Liquidia Corporation

Liquidia Corporation

LQDAยทNASDAQ

$55.69

+1.5%
HealthcareBiotechnology

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

At a Glance

Live Snapshot
Market Cap$4.95B
EPS-0.8000
P/E Ratio-69.61
Earnings Date08/11/2026

No Dividend Yield Data

LQDA has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

LQDA has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

LQDA has not reported any net dividends paid values in the available annual periods.

Liquidia Corporation

Liquidia Corporation Dividend History

LQDA ยท NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

LQDA Dividend Payment History

LQDA ยท NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
lqda

Liquidia Corporation Payout Ratio Analysis

LQDA ยท NASDAQ
Dividends Paid
0.00
2025
Net Income
-68.92M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.

Sustainability
At Risk

Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.